“The method we have developed allows us to detect targets at levels that are unprecedented,” John Brennan, director of McMaster’s Biointerfaces Institute, said in a statement. “The test has the best sensitivity ever reported for a detection system of this kind — it is as much as 10,000 times more sensitive than other detection systems.”
The tool is a molecular device made of DNA that can be triggered by a molecule of the researchers’ choosing. In the presence of an indicator for a specific disease or a molecule representing a virus, the device would signal detection.
The research was published online in the journal Angewandte Chemie International Edition.
More articles on infection control:
Infection control & quality: 2015 mid-year report
10 things to know about infection preventionists’ careers, responsibilities and more
53 hospitals with the lowest 30-day heart failure readmission rates
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
